# Roflumilast in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Fixed Combinations of Long-acting β2-agonists (LABA) and Inhaled Glucocorticosteroid (ICS)

> **NCT01329029** · PHASE4 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 1945 (actual)

## Conditions studied

- Chronic Obstructive Pulmonary Disease

## Interventions

- **DRUG:** Roflumilast
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01329029
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-05
- **Primary completion:** 2014-03
- **Final completion:** 2014-05
- **Target enrollment:** 1945 (ACTUAL)
- **Last updated:** 2016-12-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01329029

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01329029, "Roflumilast in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Fixed Combinations of Long-acting β2-agonists (LABA) and Inhaled Glucocorticosteroid (ICS)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01329029. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*